Beware of the Uric Acid: Severe Azathioprine Myelosuppression in a Patient With Juvenile Idiopathic Arthritis and Hereditary Xanthinuria

J Clin Rheumatol. 2020 Mar;26(2):e49-e52. doi: 10.1097/RHU.0000000000000838.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aldehyde Oxidase / deficiency*
  • Aldehyde Oxidase / genetics
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / pharmacokinetics
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / immunology
  • Azathioprine* / administration & dosage
  • Azathioprine* / adverse effects
  • Azathioprine* / pharmacokinetics
  • Bone Marrow Failure Disorders* / blood
  • Bone Marrow Failure Disorders* / chemically induced
  • Bone Marrow Failure Disorders* / therapy
  • Erythrocyte Transfusion / methods
  • Humans
  • IgA Deficiency / diagnosis*
  • Immune Tolerance / genetics
  • Immunologic Tests / methods
  • Male
  • Pharmacogenomic Testing / methods
  • Purine-Pyrimidine Metabolism, Inborn Errors* / diagnosis
  • Purine-Pyrimidine Metabolism, Inborn Errors* / genetics
  • Purine-Pyrimidine Metabolism, Inborn Errors* / physiopathology
  • Sulfurtransferases / genetics
  • Uric Acid* / blood
  • Uric Acid* / urine
  • Xanthine
  • Xanthine Dehydrogenase / deficiency*
  • Xanthine Dehydrogenase / genetics
  • Young Adult

Substances

  • Antirheumatic Agents
  • Xanthine
  • Uric Acid
  • Xanthine Dehydrogenase
  • Aldehyde Oxidase
  • MOCOS protein, human
  • Sulfurtransferases
  • Azathioprine

Supplementary concepts

  • Xanthinuria, Type II